Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

192
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
192
Chronic Obstructive Pulmonary Disease-V: Management01:29

Chronic Obstructive Pulmonary Disease-V: Management

2.5K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
2.5K
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

150
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
150
Chronic Obstructive Pulmonary Disease-V: Nursing Management01:30

Chronic Obstructive Pulmonary Disease-V: Nursing Management

3.7K
Nursing management of Chronic Obstructive Pulmonary Disease (COPD) is crucial for providing thorough care and support to patients. Nurses play an integral role in this process through detailed assessment, careful planning, targeted interventions, and ongoing evaluation. Here's an overview of the critical steps in nursing management for COPD.
Assessment
3.7K
Chronic Obstructive Pulmonary Disease01:22

Chronic Obstructive Pulmonary Disease

1.2K
COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
1.2K
Chronic Obstructive Pulmonary Disease-I: Introduction01:20

Chronic Obstructive Pulmonary Disease-I: Introduction

2.8K
Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.
2.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Associations Between Social Determinants of Health and Adherence to Biologic Therapies in Patients with Severe Asthma: Real-World Evidence from a Large US Claims Analysis.

Journal of asthma and allergy·2026
Same author

CAR T Cell Therapy as a Definitive Consolidation for Older Adults with B-ALL in First Complete Remission.

Blood advances·2026
Same author

Mucoactive therapies and the European Respiratory Society guideline for adult bronchiectasis: what now after the CLEAR trial?

The European respiratory journal·2026
Same author

Pilot and Feasibility Study of an Individualized Telehealth Exercise Program for People with Cystic Fibrosis.

Journal of functional morphology and kinesiology·2026
Same author

Unravelling the Links Between Gastroesophageal Reflux and Lung Disease: New Insights.

Digestive diseases and sciences·2026
Same author

Reply to Woodie et al, "Elevated risk of active tuberculosis with interleukin (IL)-17, IL-23, IL-12/23, Janus kinase inhibitors, cyclosporine, and tumor necrosis factor-α inhibitors compared with the general population: A population-based analysis using TriNetX".

Journal of the American Academy of Dermatology·2026

Related Experiment Video

Updated: Jun 17, 2025

Growing a Cystic Fibrosis-Relevant Polymicrobial Biofilm to Probe Community Phenotypes
03:53

Growing a Cystic Fibrosis-Relevant Polymicrobial Biofilm to Probe Community Phenotypes

Published on: April 19, 2024

509

Clinical perspectives in bronchiectasis management.

Nauman Chaudary, Francois Fadell, Bryan Garcia

  • 1Emory Healthcare and Winship Cancer Institute, Atlanta, GA.

The American Journal of Managed Care
|August 12, 2024
PubMed
Summary
This summary is machine-generated.

Non-cystic fibrosis bronchiectasis significantly impacts quality of life, with no US treatment guidelines or FDA-approved therapies. Experts emphasize CT scans for diagnosis and focus on managing exacerbations and improving patient HRQOL.

More Related Videos

Author Spotlight: Exploring Non-Pharmacological Therapies for Chronic Respiratory Diseases — Linking Intestinal Microbiome Insights to COPD Treatment
03:25

Author Spotlight: Exploring Non-Pharmacological Therapies for Chronic Respiratory Diseases — Linking Intestinal Microbiome Insights to COPD Treatment

Published on: December 27, 2024

792
Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

31.9K

Related Experiment Videos

Last Updated: Jun 17, 2025

Growing a Cystic Fibrosis-Relevant Polymicrobial Biofilm to Probe Community Phenotypes
03:53

Growing a Cystic Fibrosis-Relevant Polymicrobial Biofilm to Probe Community Phenotypes

Published on: April 19, 2024

509
Author Spotlight: Exploring Non-Pharmacological Therapies for Chronic Respiratory Diseases — Linking Intestinal Microbiome Insights to COPD Treatment
03:25

Author Spotlight: Exploring Non-Pharmacological Therapies for Chronic Respiratory Diseases — Linking Intestinal Microbiome Insights to COPD Treatment

Published on: December 27, 2024

792
Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

31.9K

Area of Science:

  • Pulmonology
  • Respiratory Medicine

Background:

  • Non-cystic fibrosis bronchiectasis is a chronic inflammatory airway disease causing permanent lung damage.
  • Significant clinical and economic burdens are associated with bronchiectasis.
  • Current knowledge gaps exist, including a lack of US-based treatment guidelines and FDA-approved therapies.

Purpose of the Study:

  • To summarize findings from an AJMC® roundtable discussion on non-cystic fibrosis bronchiectasis held in March 2024.
  • To contextualize expert opinions within existing scholarly literature.
  • To identify key challenges and unmet needs in bronchiectasis management.

Main Methods:

  • Convened a panel of experts for a roundtable discussion.
  • Summarized and synthesized expert opinions and recommendations.
  • Reviewed existing literature to support roundtable findings.

Main Results:

  • Recommended CT scanning for patients with symptoms like chronic cough, fatigue, purulent sputum, hemoptysis, or recurrent infections.
  • Estimated prevalence in the US affects 364,000 to 558,000 adults.
  • Highlighted that disease burden diminishes health-related quality of life (HRQOL), and exacerbations worsen prognosis.
  • Identified primary management goals as preventing exacerbations and improving HRQOL in the absence of FDA-approved treatments.

Conclusions:

  • Healthcare providers currently lack adequate tools to manage this heterogeneous disease.
  • There is a critical need for symptom management options, US-based clinical guidelines, and further research into bronchiectasis epidemiology, etiology, and treatment.